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Systemic lupus erythematosus (SLE) is a major public health problem in the United States.  It is 
estimated that at least 500,000 Americans suffer from (SLE), which is a complex autoimmune 
disease of primarily unknown etiology.  SLE is about three times more common in African 
Americans (about 1:250 incidence) than in Caucasian Americans (about 1:1000 incidence), and 
predominantly affects women of child-bearing age (female to male ratio of 9:1).  SLE causes a 
variable amount of morbidity, shortened life expectancy, and substantial total health 
expenditures, largely due to complications such as thrombosis, atherosclerosis, renal disease, and 
antiphospholipid syndrome (APS).  Genetics plays a significant role in the etiology of SLE; 
therefore, understanding the underlying genetic influence of this disease is of significant public 
health importance.  This study dealt with the analysis of one of the genes that has been proposed 
to play a role in the pathogenesis of SLE: apolipoprotein H (APOH gene, apoH protein), also 
referred to as β2-glycoprotein I (β2-GPI).  ApoH is thought to have anti-atherogenic properties 
and has been shown to be a major target antigen for antiphospholipid antibodies (APA) present 
in patients with APS.  Twelve APOH SNPs (9 TagSNPs and 3 additional functional coding 
SNPs) were genotyped in 398 women with a clinical diagnosis of SLE and 496 healthy women 
as controls.  The associations of allele and genotype distributions of these 12 SNPs with SLE, 
race, renal disease in white patients, and APA in black and white patients and controls were 
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analyzed.  Significant allelic distribution differences were observed between whites and blacks 
for 9 of the 12 SNPs, indicating a race-dependent variation.  No associations were found between 
genotype distributions in any of the 12 SNPs and SLE, renal disease, or APA status. However, 
haplotype analysis revealed six haplotypes that significantly differed in frequency between cases 
and controls.  Of particular interest was one haplotype that was present in 16.2% of cases and 
0.6% of controls, suggesting a potential risk factor for SLE.  In conclusion, our study suggests 
that combined effects of APOH SNPs (haplotype) may be implicated in modifying the risk of 
SLE. 
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1.0  BACKGROUND AND SIGNIFICANCE 
1.1 INTRODUCTION TO LUPUS 
Systemic lupus erythematosus (SLE or lupus) is a multifactorial, chronic autoimmune 
disorder characterized by complex pathophysiology involving many organ systems, including 
dermatologic, renal, central nervous system (CNS), hematologic, musculoskeletal, 
cardiovascular, pulmonary, the vascular endothelium, and gastrointestinal.  Symptoms include 
malar or discoid rash, photosensitivity, oral ulcers, arthritis, serositis, renal complications, 
neurologic disorder, hematologic involvement, or the presence of antinuclear antibodies (ANA).  
SLE presents in periods of flares (an acute increase in symptoms) and remission (Trethewey, 
2004). 
Lupus is a relatively common disease, affecting an estimated 500,000 or more Americans 
(Trethewey, 2004).  The overall incidence is in the range of 1.8-7.6 cases per 100,000 per year in 
the United States, with variable incidence worldwide.  The epidemiology of SLE is striking in 
that 80% of cases are women between the ages of 15 and 45 (essentially those of childbearing 
age).  Studies have shown that women taking oral contraceptives or hormone replacement are at 
increased risk to develop SLE, suggesting a hormonal role in disease etiology.  The male to 
female ratio is 9:1.  Although SLE appears in all ethnic groups, it is more common among 
certain populations – it is three times more common in African Americans (about 1:250 
incidence) than in Caucasian Americans (about 1:1000 incidence) (Lamont, 2006). 
A genetic component of lupus is supported by the fact that the disease is more likely to 
occur among first-degree relatives (familial prevalence of 10-12%), and concordance rates are 
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higher in monozygotic twins (24-58%) than in dizygotic twins (2-5%) (Brent, 2007).  The risk of 
an SLE sibling compared to the general population risk has been reported between 20-40 (Nath 
et al. 2004).  These concordance rates, however, are relatively low, suggesting that 
environmental factors also play a role in the onset of disease.   
Autoantibodies, circulating immune complexes, and T lymphocytes all contribute to the 
expression of SLE in the different organs and cell types.  Autoantibodies are produced against 
various antigens, including nuclear, cytoplasmic, and blood cell surface antigens, which in turn 
leads to accumulation of immune complexes within the blood vessel walls and subsequent 
symptoms (Trethewey, 2004).   
Although the prognosis of SLE patients has improved over time, the 10-year survival rate 
is about 80% and the 20-year survival rate is about 70%.  Early deaths are often caused by active 
disease, while atherosclerosis and acute myocardial infarction are among the most common 
causes of mortality later in the disease course (Urowitz, 1976).  Lupus nephritis and infection are 
leading causes of death at any stage of SLE.  Other causes of morbidity and mortality include 
antiphospholipid syndrome (APS), carditis, pneumonitis, pulmonary hypertension, stroke, 
myocardial infarction, and cerebritis – all of which may lead to thrombosis (Lamont, 2006). 
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1.2 RENAL MANIFESTATIONS OF SLE 
One of the more severe manifestations of SLE, lupus nephritis, usually develops within 
five years of a diagnosis based on the American College of Rheumatology classification criteria.  
The prevalence of clinical renal involvement in persons with SLE is estimated to be 30-90%, 
with severity and prevalence estimates of lupus nephritis tending to be higher in the Black and 
Asian populations and in children (Brent, 2007).  
The pathogenesis of lupus nephritis is due largely in part to the production of 
autoantibodies directed against nuclear elements, which form immune complexes.  In the 
kidneys, deposition of these immune complexes initiates an inflammatory response by activating 
the complement cascade and recruiting inflammatory cells.  Histological evidence of lupus 
nephritis is present in most patients with SLE, even if they do not have clinical symptoms of 
renal disease (Brent, 2007). 
Results from a study by Matsuda et al. (1993) suggested that patients with SLE were 
positive for apoH-dependent anticardiolipin (aCL), while lupus anticoagulant (LAC) and apoH-
independent aCL were produced in patients with end-stage renal disease (not related to SLE), 
especially those on hemodialysis.  A study by Frostegård et al. (2005) showed that SLE patients 
with cardiovascular and renal involvement had more oxidized epitopes on low-density 
lipoproteins (LDL) compared with controls. Furthermore, aCL in these patients recognized 
epitopes generated during lipid peroxidation. Therefore, "neo" self antigens on lipoproteins, 
generated during oxidation, are present in SLE and may be of importance for the development of 
premature cardiovascular disease and possibly also for other autoimmune phenomena observed 
in SLE. 
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1.3 CARDIOVASCULAR MANIFESTATIONS OF SLE 
Cardiovascular involvement is frequently reported in SLE patients, with estimates 
ranging from 6.1 to 8.9 percent of cases (Manzi, 1997).  In a study by Manzi et al. (1997), a 
sample of 35-44 year old women with SLE was found to have an incidence of myocardial 
infarction 50 times higher than the general population.  Such an increase in premature 
cardiovascular disease is thought to be attributable to multiple factors, including underlying 
vascular inflammation and arterial wall injury, corticosteroid use, renal disease, hypertension, 
antiphospholipid antibodies and thrombosis – all of which are common in women with SLE.   
Several studies have also reported atherosclerotic vascular disease as a major finding in 
SLE women with cardiovascular events.  Treatment with corticosteroids, renal disease, and 
hypertension are thought to play a role in the atherosclerotic process in these women.  One study, 
however, showed that these “Framingham risk factors,” as they are called, failed to serve as a 
sufficient explanation for the accelerated atherosclerosis observed (Esdaile, 2001). 
Atherosclerosis is a progressive condition that begins with the formation of macrophage-
derived foam cells.  Foam cells are created when circulating lipoproteins, mainly from pro-
atherogenic low-density lipoproteins (LDL), are taken up by macrophages.  Before these LDLs 
can be taken up by macrophages, however, they must be modified.  One such modification 
process is peroxidation, or the conversion of LDL to oxidized LDL (oxLDL) which is taken up 
by scavenger receptors.  Thus, excessive intracellular accumulation of oxLDL encourages plaque 
(atheroma) formation (Ross, 1999; Matsuura, 2006).   
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Figure 1. Enlarged views of atherosclerosis (Keller, 2004) 
1.4 ATHEROSCLEROSIS AND APOH 
Apolipoproteins associate with lipoproteins and are integrated in lipoprotein particles 
such as LDL, high density lipoproteins (HDL), very low density lipoproteins (VLDL), and 
chylomicrons (CM).  The focus of this study is on human apolipoprotein H (APOH gene, apoH 
protein), also referred to as β2-glycoprotein I (β2-GPI).  This well-characterized apoH protein is a 
constituent of triglyceride rich lipoproteins in human lymph and plasma and is thought to play a 
role in triglyceride metabolism, via activation of lipoprotein lipase (Polz, 1979; Nakaya, 1980).  
ApoH is responsible for 17% of the composition of HDLs, 16% of CMs and VLDLs, and 2% of 
LDLs (Lozier et al. 1984).   
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There is also evidence that apoH binds to platelets and regulates adenylate cyclase 
activity (Schousboe, 1980).  Moreover, apoH has been shown to be involved in cholesterol 
transport, foam cell formation, and consequently atherosclerosis.  Lin et al. (2001) showed that 
apoH has an “antioxidant”-like effect on LDL oxidation; by increasing cholesterol efflux and 
decreasing cholesterol influx, apoH decreases cellular accumulation of cholesterol.  In addition, 
Lin et al. (2001) reported that apoH inhibits the translocation of cholesterol from extracellular 
pools to macrophages, thus possibly lending to the prevention of atherosclerosis. 
Further evidence that apoH may be an anti-atherogenic protein was provided by a study 
by Hasunuma et al. (1997) that suggested a dual role of apoH in the uptake of oxLDL by 
macrophages.  This study demonstrated that apoH inhibits the uptake of oxLDL in the absence of 
anticardiolipin (aCL), while the binding of oxLDL was significantly increased by the 
simultaneous addition of human apoH and monoclonal aCL, indicating an atherogenic effect. 
ApoH is known to be the actual target antigen for clinically relevant antiphospholipid 
antibodies such as aCL (Hunt et al. 1992).  Certain groups of aCLs (anti-apoH antibodies) exert 
lupus anticoagulant (LAC) activity and disrupt the function of vascular endothelial cells.  Lupus 
anticoagulants, antibodies against anionic phospholipids or associated proteins which inhibit 
phospholipid-dependent blood coagulation, are often found in patients with SLE.  Takeya et al. 
(1997) showed that anti-apoH monoclonal antibodies (mAbs) enhance the binding of apoH to 
phospholipids, thus exerting LAC activity.  This congregation of apoH molecules on the surface 
of phospholipids is thought to cause rigidness of the phospholipid surface and to subsequently 
reduce the lateral mobility of clotting factors toward the prothrombinase complex on this surface.  
Further evidence of this theory was provided by a study that showed antiphospholipid antibodies 
may promote thrombosis at the locations where fetal cells make contact with maternal blood and 
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where vascular endothelial cells are exposed to circulating blood by reducing the levels of 
annexin V and accelerating the coagulation of plasma on cultured trophoblasts and endothelial 
cells (Rand et al. 1997).  This process may be relevant to thrombosis and pregnancy loss in 
patients with antiphospholipid syndrome (APS), a condition that occurs with relative frequency 
in patients with SLE. 
1.5 ANTIPHOSPHOLIPID SYNDROME (APS) AND ApoH 
Antiphospholipid syndrome (APS) is one of the most common causes of 
hypercoagulability in the general population (Ginsburg et al. 1992).  Primary APS occurs in the 
absence of underlying disease, while secondary APS may occur in the context of autoimmune 
disorders such as SLE.  APS is characterized by elevated serum levels of antiphospholipid 
antibodies (APA), venous or arterial thromboembolic events, or pregnancy morbidity (Hanly, 
2003).   
Antiphospholipid antibodies include a heterogeneous family of immunoglobins.  They 
may be produced transiently and in low concentrations in up to 5% of healthy individuals. 
However, APA are found in higher frequency and concentration in individuals with autoimmune 
and other conditions such as syphilis, HIV, and other infections and malignancies (Levine et al. 
2001).  APA are present in up to 50% of SLE patients (Carsons, 2004).  The most common APA 
that are clinically detected for APS are aCL and LAC, which studies have estimated to be present 
in 12%-30% and 15%-34% of SLE patients, respectively (Hanly, 2003).  These APA recognize 
phospholipid binding proteins such as apoH and prothrombin.  Further, the autoimmune aCL 
from patients with SLE and APS requires apoH as a cofactor in order to bind to cardiolipin (CL) 
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directly (as opposed to aCL binding directly to CL in patients with various infectious diseases 
and low incidence of thrombosis) – this is termed apoH-dependent aCL (Matsuura at al. 2006). 
It has been shown by RT-PCR analysis that apoH mRNA is expressed in several cells 
which are targeted by autoantibodies in APS, such as endothelial cells, astrocytes, neurons, and 
lymphocytes.  These cell types were found to be immunoreactive to anti-apoH mAbs in the same 
study by immunofluorescence technique, indicating an antigenic function of apoH in APS 
(Caronti et al. 1999).  ApoH has also been found to be expressed in the liver and in enterocytes 
(gastrointestinal cells) at both the mRNA and protein levels (Averna et al. 1997). 
 
 
 
Figure 2. Pathogenic mechanism in antiphospholipid syndrome (Hanly, 2003) 
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1.6 MOLECULAR ASPECTS OF ApoH 
ApoH is a single-chain 50-kDa glycoprotein composed of 326 amino acids that exists in 
both a free form and in combination with lipoprotein particles (Lozier et al. 1984).  
Schwarzenbacher et al. (1999) determined the crystal structure of β2-GPI and revealed that there 
are five domains, including four complement control protein (CCP) modules and a positively 
charged fifth C-terminal domain, arranged like beads on a string to form a J-shaped molecule 
(Figure 3).  This fifth domain is capable of binding negatively charged substances such as  
phospholipids, platelets, and viral proteins.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The secondary structure of apoH shown as a ribbon drawing (Schwarzenbacher et al. 1999) 
 
The chromosomal location of APOH is 17q23-17q24.  The gene is 18kb long and 
contains 8 exons.  Exon 1 contains the 5′ untranslated region (5′UTR) and the signal peptide 
coding sequences.  The transcriptional initiation site (said to be at +1) is located 31bp upstream 
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of the translational start codon.  Exons 2 through 7 code for short consensus repeats (SCRs). 
SCRs 1, 3, 4, and 5 are coded by exons 2, 5, 6, and 7, respectively, while SCR2 is coded by 
exons 3 and 4.  Exon 8 encodes the 3′UTR, stop codon, and C-terminus (Okkels et al. 1999). 
1.7 APOH POLYMORPHISMS 
Several studies have successfully identified functional polymorphisms in APOH, 
particularly in the coding regions.  Sanghera et al. (1997b) identified two common structural 
missense mutations in the fifth domain which prevent apoH from binding to negatively charged 
phosphatidylserine (PS).  These mutations are located at Trp316Ser (TGG → TCG), and 
Cys306Gly (TGC → GGC).  Mehdi et al. (2000) went on to describe how these missense 
mutations disrupt binding of apoH to CL.   
In 1993, Steinkasserer et al. described a missense mutation in APOH exon 7 at 
Val247Leu (GTA → TTA).  Takada et al. (2003) investigated the impact of this 247Leu allele 
and a splice-site mutation of the LD receptor (LDLR) gene on familial hypercholesterolemia by 
performing an intra-familial correlation analysis in an eight-generation extended family, in which 
members were affected with either type IIa hyperlipoproteinemia (HLPIIa), type IIb 
hyperlipoproteinemia (HLPIIb), or no disease.  All family members with HLPIIb were found to 
have both the deleterious LDLR allele and an apoH 247Leu allele, whereas all members with 
HLPIIa had the defective LDLR allele and the apoH 247Val allele.  The results of this study 
indicate that the Val247Leu mutation in apoH plays a role in modifying the phenotype of FH in 
individuals with an LDLR mutation.   
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The APOH gene has been shown to have structural polymorphism with five alleles: 
APOH*1, APOH*2 (the most common), APOH*3W and APOH*3B (based on reactivity with an 
APOH monoclonal antibody in whites and blacks, respectively), and APOH*4 (only found in an 
African American population (Kamboh et al. 1988).  Significant inter-racial differences in the 
frequencies of these alleles has been observed.  The molecular basis for the apoH protein 
polymorphism has now been analyzed to some extent.  Four mutations in exon 5, which codes 
for the third domain of apoH, were identified, including a point mutation at Ser140Ser (TCA → 
TCG) and missense mutations at Ile122Thr (ATC → ACC), Arg135His (CGT → CAT), and 
Ala141Asp (GCT → GAT).  A point mutation at the intron 4/exon 5 junction at the location of   
-10 (A → C) was also identified (Kamboh et al. 2004).  The three missense mutations were 
shown to decrease CL binding with apoH, suggesting that the third domain plays a role in this 
function.  Interestingly, these mutant alleles at codons 122, 135, and 140 were found to be in 
significant linkage disequilibrium with the common polymorphism at codon 247.   
Several missense mutations were found by Kamboh et al. (2004) to correspond to APOH 
alleles in haplotype combination: APOH*3 (122Thr/135His), APOH*3B 
(122Thr/135His/141Asp), and APOH*3W (122Thr/135His/316Ser).  Further, two missense 
mutation in codon 3 (Ser88Asn) and codon 316 were found to correspond to APOH*1 and 
APOH*3, respectively (Sanghera et al. 1997a; 1997b).  The previously identified mutations at 
codon 247 and codon 306 have not been found to be associated with a particular apoH protein 
polymorphism.  Based on the results of an analysis of the evolutionary pathway of APOH 
haplotypes, Kamboh et al. (2004) proposed a revised nomenclature of the alleles.  In this new 
naming system, the original APOH*3B is now APOH*3 and the original APOH*4 is now 
APOH*3B. 
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1.8 APOH TAG SNPS 
Single nucleotide polymorphisms (SNPs) are single base pair differences in a genetic 
sequence that are relatively common (defined as more than 1% of individuals in a population).  It 
is estimated by the International HapMap project that SNPs occur in our genome with a 
frequency of about one in every 1,200 bases.   
SNPs that are in close proximity to each other tend to be inherited together.  Such clusters 
of SNPs are termed haplotypes.  “Tag” SNPs are a set of SNPs that uniquely identify a particular 
haplotype.  This project aims to genotype select Tag SNPs in APOH in order to delineate any 
possible associations between our population of SLE patients, renal disease, race, APA 
involvement, and APOH haplotypes.  If individuals with SLE, renal disease, or APA tend to 
share a particular haplotype, variants contributing to the disease might be somewhere within or 
near that haplotype. 
The functional polymorphisms that have been identified in previous studies of APOH 
have been located in the coding regions of the APOH gene.  However, it is also possible for 
polymorphisms in the non-coding regions of a gene to have an impact on phenotype.  For 
example, recent findings have indicated that a polymorphism (G/A) in intron 4 of the 
programmed cell death 1 (PDCD1) gene may be associated with sporadic SLE risk (Sanghera et 
al. 2004).  In addition, a SNP (T/G) at position -93 in the promoter region of the lipoprotein 
lipase gene was shown by Hall et al. (1997) to impact triglyceride levels – individuals who were 
homozygous for the T allele were reported to have lower triglyceride levels. 
For this study, nine Tag SNPs were analyzed, five of which are located in introns, one in 
the promoter region, one in the 3′UTR, one in the 3′ flanking region, and one in the coding 
region.  Three additional non-synonymous coding SNPs were also included in this analysis.  A 
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summary of information about these SNPs is included in Table 1.  The University of 
Washington-Fred Hutchinson Cancer Research Center group has sequenced the APOH gene and 
identified 146 SNPs (http://pga.gs.washington.edu/data/apoh/).  Information about the minor 
allele frequencies (MAF) of these SNPs in populations of European and African descent has 
been reported and is included for the SNPs relevant to this study in Table 1.  The MAF for 
APOH/rs1801689 is marked with an ‘*’ because these percentages were not available from the 
Seattle SNP database.  MAF for APOH/rs1801689 was obtained from the International HapMap 
project (http://www.hapmap.org).   For each SNP, the reference SNP (refSNP) ID from NCBI is 
also listed, along with the corresponding nucleotide substitution.  The nine TagSNPs are marked 
in blue font (Table1).  
Table 1. SNPs used for statistical analysis in this study 
Db SNP ID APOH 
Location 
Seattle SNP Site SNP MAF in 
Whites 
MAF in 
Blacks 
rs3760292 Promoter -643 T>C 17% 17% 
rs8178826 Intron 2 3470  A>G 5% 0% 
rs8178839 Intron 4 7381 T>G 7% 17% 
rs8178847 Exon 5 10059 
(Codon 135) 
G>A 
(Arg>His)
7% 5% 
rs8178848 Intron 5 11251 G>A 5% 3% 
rs2873966 Intron 6 14905  G>A 22% 19% 
rs8178858 Intron 6 15320  G>A 24% 5% 
rs3176975 Exon 7 16121 
(Codon 247) 
G>T 
(Val>Leu)
26% 50% 
rs1801689 Exon 7  
(Codon 306) 
T>G 
(Cys>Gly)
2.5%* 0%* 
rs1801690 Exon 8 18593 
(Codon 316) 
G>C 
(Trp>Ser) 
2% 0% 
rs6933 3′UTR 18648 A>G 48% 18% 
rs7211492 3′ Region 20246  A>G 12% 3% 
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1.9 SPECIFIC AIMS 
The specific aims of this study include the following: 
1) To determine the allele frequency and genotype distributions of APOH SNPs among 
white and black subjects from Pittsburgh.  
a. H0 – no significant differences will be observed in the allele frequencies of 
APOH SNPs between white and black subjects 
b. H1 – a significant difference will be observed in the allele frequencies of 
APOH SNPs between white and black subjects 
2) To determine the association of APOH SNPs with SLE in white and black subjects. 
a. H0 – no association will be observed between APOH SNPs and SLE 
b. H1 – an association will be found between APOH SNPs and SLE 
3) To determine the association of APOH SNPs with renal involvement in white patients 
and antiphospholipid antibodies (APA) in white and black patients and controls. 
a. H0 – no association will be observed between APOH SNPs and renal disease 
or APA in white patients with SLE 
b. H1 – an association will be found between APOH SNPs and renal disease or 
APA in white patients with SLE 
4) To determine the association of haplotypes, including nine APOH TagSNPs with SLE 
in white patients 
a. H0 – no association will be observed between APOH haplotypes and SLE 
b. H1 – an  association will be found between APOH haplotypes and SLE  
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2.0  PATIENTS AND METHODS 
2.1 SUBJECTS 
2.1.1 Sample Populations 
DNA (obtained from leukocytes) and blood sera from 398 women with a diagnosis of 
SLE were used for analysis in this study.  All subjects were recruited through a study by Dr. 
Susan Manzi, in which the prevalence of cardiovascular disease and other risk factors in women 
with SLE were evaluated.  All of the study participants met the American College of 
Rheumatology criteria for the classification of SLE (Tan et al. 1982; Hochberg 1997).  This 
cohort consisted of women ranging in age from 18 to 79 years (mean age 43.23 years +/− 11.43 
SD).  350 of the women were Caucasian, while 48 were African American.  Lupus nephritis was 
diagnosed in the SLE patients based on either renal biopsy, proteinuria (at least 2 measurements 
of >0.5 gm/24 hours or 3+ protein by dipstick), or the presence of red blood cell casts (Tripi et 
al. 2006).   
A cohort of 496 control samples from the same geographic location as the SLE group 
was obtained from the Central Blood Bank of Pittsburgh.  These individuals were described as 
“healthy” and had no apparent history of SLE or related rheumatologic disease.  This cohort 
consisted of women ranging in age from 17 to 81 years (mean age 45.63 years +/− 13.47 SD).  
454 of the women were Caucasian, while 42 were African American.  The University of 
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Pittsburgh Institutional Review Board approved this study, and all participants underwent the 
informed consent process. 
2.1.2 Antiphospholipid antibody quantification from patient samples 
Serum samples from all patients and controls were screened in duplicate for the presence 
of aCL (both IgG aCL and IgM aCL), LAC, and anti-apoH as previously described (Sanghera et 
al. 2004; Tripi et al. 2006).  All subjects who were positive for at least one of these antibodies 
were considered to be positive for antiphospholipid antibody (APA). 
2.2 DETERMINATION OF GENOTYPES 
2.2.1 Pyrosequencing 
Polymerase chain reaction (PCR) was used to amplify DNA samples for two TagSNPs 
(APOH/rs8178848 and APOH/rs8178826) prior to genotyping by Pyrosequencing.  For each 
sample, DNA was combined with 10X PCR buffer II (Applied Biosystems), 50mM MgCl2 
(Applied Biosystems), 1.25mM dNTPs (GE Healthcare), 1.25 units of AmpliTaq DNA 
Polymerase (Applied Biosystems), 20μM forward primer (biotin-labeled) and 20μM reverse 
primer (Invitrogen). For each primer set, the forward primer was labeled with biotin.  Quantities 
of reagents used for optimum amplification of each fragment are listed in Table 2. 
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Table 2. PCR Reaction Mixtures 
 APOH/ rs8178848 APOH/rs8178826 
 SLE/CBB (WGA) SLE/CBB (WGA) 
DNA 2.0μl 4.0μl 
10X Buffer 5.0μl 5.0μl 
MgCl2 5.0 μl 4.0μl 
dNTPs 3.5μl 3.5μl 
Forward Primer 0.5μl 0.4μl 
Reverse Primer 0.5μl 0.4μl 
Taq Polymerase 0.25μl 0.25μl 
 
A thermal cycler (GeneAmp PCR System 9700, Applied Biosystems) with heated lid was 
used to regulate the temperature cycles required for PCR.  The PCR conditions for these two 
TagSNPs are outlined in Table 3, along with the primers used (written in the 5' to 3' direction): 
Table 3. PCR Conditions 
 APOH/rs8178848 APOH/rs8178826 
 
PCR 
Conditions 
95°C for 5 min. – 1 cycle 
95°C for 30 sec. 
60°C for 30 sec. } 45 cycles 
72°C for 40 sec. 
72°C for 5 min. – 1 cycle  
95°C for 5 min. – 1 cycle 
95°C for 30 sec. 
60°C for 20 sec. } 45 cycles 
72°C for 30 sec. 
72°C for 5 min. – 1 cycle  
 
 
Primer 
Sequences 
Forward Primer - Biotin Labeled: 
CAGCATGGAGGAGCTACCAATAA
Reverse Primer: 
TGCCTGGCCCATAGTTGAG  
Forward Primer – Biotin Labeled: 
CCTTTGTCAAAGTTATGCATGTTC 
Reverse Primer: 
GGCTCTTTAAGCAAAAAAGCATAG
 
The success of PCR was confirmed via gel electrophoresis of approximately 30% of the 
samples.  To a gel consisting of 2% agarose in TBE buffer (tris, boric acid, and disodium EDTA 
dihydrate) with 0.8% ethidium bromide (Amresco), 5μl of marker dye (0.25% Orange G, Sigma) 
and 7μl of PCR product was added for each sample.  The samples were subjected to 
electrophoresis for about 35 min at 250V.   
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The genotypes of APOH/rs8178848 and APOH/rs8178826 were analyzed using the 
Pyrosequencing technology designed and produced by Biotage.  Pyrosequencing is a fairly novel 
method of genotyping SNPs and insertion/deletion polymorphisms (InDels) either individually or 
in multiplex analysis.  Although multiplex analysis was attempted for this study, the particular 
Pyrosequencing assays for these TagSNPs were not appropriate for duplex analysis; therefore, 
simplex (individual) analysis was performed.  Table 4 lists the conditions of these assays: 
Table 4. Pyrosequencing Assay Conditions 
 PYROSEQUENCING ASSAYS 
 
 
APOH/rs8178848 
Sequencing Primer: 
5’TGGCCCATAGTTGAG 
Sequence Analyzed: 
TA/GCCCAGA AAGGTACAAG TTACTACTG 
 
APOH/rs8178826 
Sequencing Primer: 
5’GCAAAAAAGCATAGTAAAAT 
Sequence Analyzed:
CAACTTGCA/ GTGAACATGC ATAACTTTGA CAAAGG
 
A TagSNP in the promoter region, APOH/rs3760292 (position -643), was also previously 
analyzed via Pyrosequencing in the sample populations (Erin Jacobs, 2005, data not yet 
published).  This data was utilized for the statistical analyses performed in this study. 
The biochemical principle of Pyrosequencing is outlined briefly as follows: proceeding 
PCR amplification of the SNPs and agarose electrophoresis with ethidium bromide staining as a 
quality control check, PCR products are processed in order to render them single-stranded, which 
is necessary for the sequencing primer to anneal (Ronaghi et al, 1996).  This single-stranded 
DNA (ssDNA) is obtained by mixing the PCR product (in this case, 18μl was used per sample) 
with streptavidin-coated beads, which bind to the biotinylated strand of the DNA double helix.  
Alkalai solutions are then used to neutralize the pH and separate the non-biotinylated from the 
biotinylated strands that are attached to the beads.  A Vacuum Prep Tool is used to capture the 
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beads and transfer them to annealing buffer containing 10mM sequencing primer diluted in 
annealing buffer.  The primer is annealed to the ssDNA template via heating to 90°C for 2 
minutes, then cooling at room temperature (Biotage, 2006; Gharizadeh, 2002).   
Next, enzymes including DNA polymerase, ATP sulfurylase, luciferase, and apyrase are 
added by the PSQ-96MA apparatus.  The substrates, adenosine 5’ phosphosulfate and luciferin, 
are then added.  The first deoxyribonucleotide triphosphate (dNTP) in the dispensation order is 
released; if it is complimentary to the first unpaired base in the template strand, then DNA 
polymerase facilitates its incorporation and pyrophosphate (PPi) is released in quantities 
proportionate to the number of that particular dNTP available in sequence (Figure 3). 
The next step in this chain of reactions is the conversion of PPi to ATP by ATP 
sulfurylase in the presence of adenosine 5’ phosphosulfate. The ATP, which is produced in equal 
proportion to the amount to PPi, fuels the conversion of luciferin to oxyluciferin by luciferase – a 
reaction that produces light in an amount proportional to the amount of ATP.  A camera detects 
this quantity of light and the computer program produces a diagram of peaks that correspond to 
the addition of each dNTP (referred to as a Pyrogram).  Between the addition of dNTPs, apyrase 
degrades the unincorporated nucleotides and ATP so that the next peak can be measured from 
the same initial baseline.  This process generates a record of nucleotide sequence, and thus the 
genotype of interest (Figure 4).   
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 Figure 4. Schematic representation of the principle of pyrosequencing (Biotage, 2006) 
 
Pyrosequencing data is produced and analyzed with software that works in concert with 
the PSQ-96MA.  Following automatic data analysis, manual changes may be made at the user’s 
discretion.  Included here are the theoretical histograms corresponding to the two 
Pyrosequencing assays performed in this study, along with sample Pyrograms for each TagSNP 
(Figures 5, 6, 7, and 8). 
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Figure 5. Theoretical outcomes of simplex entry APOH/rs8178848 
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Figure 6. Representative pyrograms of simplex entry APOH/rs8178848 
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Figure 7. Theoretical outcomes of simplex entry APOH/rs8178826 
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 Figure 8.  Representative pyrograms of simplex entry APOH/rs8178826 
2.2.2 TaqMan Analysis  
The genotypes of APOH/rs2873966, APOH/rs3176975, APOH/rs6933, 
APOH/rs7211492, APOH/rs8178839, and APOH/rs8178858 were analyzed using pre-made 
TaqMan® SNP Genotyping Assays (Applied Biosystems, Foster City, CA).  The assay 
identification numbers for each TagSNP are listed in Table 5.   
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 Table 5. TaqMan® SNP Genotyping Assays 
APOH TagSNP reference sequence number TaqMan® Genotyping Assay 
APOH/rs2873966 7567311 (functionally tested) 
APOH/rs3176975* C___2658421_1_ (validated) 
APOH/rs6933 29504985 (functionally tested) 
APOH/rs7211492 16090146 (functionally tested) 
APOH/rs8178839 29176909 (functionally tested) 
APOH/rs8178858 29992830 (functionally tested) 
*This TagSNP was previously analyzed by Kamboh et al. (1999, 2004) 
 
TaqMan is a two-step procedure that requires amplification of the product and a 
subsequent endpoint reading using the ABI Prism 7900HT Sequence Detection System (Applied 
Biosystems).  The TaqMan protocol involves filling 384-well plates with purified genomic DNA.  
To this, Genotyping Assay Mix is added; this mix contains sequence-specific forward and 
reverse primers, one TaqMan minor groove binder (MGB) probe labeled at the 5′ end with VIC 
dye and one TaqMan MGB probe labeled at the 5′ end with FAM dye to detect the respective 
alleles.  A nonfluorescent quencher (NFQ) is attached to the 3′ end of the probes.  PCR is 
performed using a PTC-200 Peltier Thermal Cycler (MJ Research) with a temperature cycle 
described in Table 6:  
 
Table 6. Thermal Cycler Conditions for TaqMan® 
Times and Temperatures 
Initial Step Denaturation Primer Annealing & Extension 
HOLD 40 Cycles 
10min @ 95°C 15sec @92°C 1min @ 60°C 
 
During the annealing step, each TaqMan MGB probe anneals to the sequence between 
the forward and reverse primers.  AmpliTaq Gold DNA polymerase cleaves only probes that 
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hybridize to the target sequence; the process results in separation of the reporter dye from the 
quencher dye, and a consequent release of fluorescence.  When probes do not hybridize to the 
target sequence, the reporter dye and quencher dye essentially “cancel each other out” and 
fluorescence is suppressed; this is termed Förster-type energy transfer (Förster, 1948). This 
selective annealing of TaqMan MGB probes, therefore, enables allelic discrimination.  Figure 9 
illustrates the fluorescent outcomes of probe matches and mismatches (Livak et al. 1995). 
 
 
 
Figure 9. Schematic representation of TaqMan probe-target matches and mismatches 
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2.3 STATISTICAL METHODS 
Allele frequencies for each TagSNP were calculated by the allele counting method.  
Observed genotype frequencies were compared to Hardy-Weinberg equilibrium (HWE), and the 
significance of differences was tested by the Chi-squared goodness-of-fit test.  The significance 
of deviations between genotype frequencies and allele frequencies was tested by Fisher’s exact 
test and standard Z-test of two binomial proportions, respectively.  These tests were used for 
association analyses of allele and genotype distributions of 12 APOH SNPs with SLE, race, renal 
disease in white patients, and APA in black and white patients and controls stratified by racial 
group.  Due to the small size of our black population, renal disease association tests were 
performed for white subjects only, and antibody association studies were performed on 
combined data for black and white subjects as well.  All computations were performed using the 
R statistical software package (Version 2.1.1, http://www.r-project.org).  Linkage disequilibrium 
(LD) between SNPs was estimated by both D′ and r2 calculations using Haploview statistical 
software.  Haplotype analysis was performed using both EH and R statistical software programs.   
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3.0  RESULTS 
3.1 HARDY-WEINBERG EQUILIBRIUM (HWE) OF APOH SNPs 
For all APOH SNPs that were genotyped, observed genotype frequencies were found to 
be in Hardy-Weinberg equilibrium (HWE) for our white population.  HWE P-values could not 
be accurately estimated for the black population due to small sample size (Table 7). 
Although the genotypes of several samples could not be determined by the methods used 
in this study, the overall failure rate was less than 10% for each of the genotyped SNPs.  Failure 
rates for each individual SNP were as follows: APOH/rs8178848 (1.34%), APOH/rs8178826 
(4.47%), APOH/rs2873966 (1.23%), APOH/rs6933 (3.91%),  APOH/rs7211492 (0.67%), 
APOH/rs8178858 (9.50%), APOH/rs8178839 (1.12%). 
All failed samples were repeated, as well as 10% of the successfully genotyped samples 
to check genotyping error.   Genotyping error was calculated as the number of repeated samples 
with contradictory genotypes dived by the total number of repeated samples for each SNP.  This 
error rate was well below 3% for most of the SNPs analyzed here, and genotyping error rates for 
each individual SNP were as follows: APOH/rs8178848 (0.32%), APOH/rs8178826 (0.0%), 
APOH/rs2873966 (0.36%), APOH/rs6933 (2.69%),  APOH/rs7211492 (0.71%), 
APOH/rs8178858 (2.68%), APOH/rs8178839 (1.08%). 
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 Table 7. HWE of APOH SNPs 
rs8178848 rs8178839 
  Cases Controls   Cases Controls 
HWE white P=0.051 P=0.5991 HWE white P=0.2467 P=0.1939 
HWE black P=0.0132 P=<0.0005 HWE black P=0.9609 P=0.4299 
      
rs2873966 rs8178826 
  Cases Controls   Cases Controls 
HWE white P=0.6692 P=0.8913 HWE white P=0.8008 P=0.7348 
HWE black P=0.001 P=0.8788 HWE black P= ---- P= ---- 
      
rs7211492 rs6933 
  Cases Controls   Cases Controls 
HWE white P=0.3013 P=0.3612 HWE white P=0.4308 P=0.9151 
HWE black P=0.7632 P=0.8728 HWE black P=0.121 P=0.549 
      
rs3760292 rs8178858 
  Cases Controls   Cases Controls 
HWE white P=0.8351 P=0.4157 HWE white P=0.6756 P=0.6406 
HWE black P=0.6181 P=0.4683 HWE black P=0.3823 P= ---- 
      
rs8178847 rs3176975 
  Cases Controls   Cases Controls 
HWE white P=0.5633 P=0.6367 HWE white P=0.4002 P=0.5422 
HWE black P=0.3187 P=0.7771  HWE black P=0.5134 P=0.0573 
      
rs1801689 rs1801690 
  Cases Controls   Cases Controls 
HWE white P=0.2495 P=0.3592 HWE white P=0.9221 P=0.3378 
HWE black P= ---- P= ---- HWE black P= ---- P=0.9370 
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3.2 DISTRIBUTION OF APOH SNPS IN WHITES AND BLACKS 
The genotype and allele frequencies of twelve APOH SNPs were compared between 
white and black subjects (Table 8).  A significant difference in genotype distribution between 
races was found for APOH/rs2873966 (p=0.001), APOH/rs6933 (p=0.003), APOH/rs8178858 
(p=0.025), APOH/rs3176975 (p=<0.0001), APOH/rs1801689 (p=0.021), and APOH/rs1801690 
(p=0.012).   
Allele frequencies were significantly different (p≤0.050) for all SNPs except three: 
APOH/rs8178839 (p=0.558), APOH/rs8178848 (p=0.718), and APOH/rs8178847 (p=0.555). 
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Table 8. Distribution of APOH SNPs in whites and blacks 
APOH Genotype/   APOH Genotype/   
SNP Allele Whites Blacks SNP Allele Whites Blacks 
rs3760292 Genotypes n(%) n(%) rs2873966 Genotypes n(%) n(%) 
  TT 537(72.67) 66(82.50)  GG 397(50.06) 61(68.54)
  TC 184(24.90) 14(17.50)  GA 325(40.98) 27(30.34)
  CC 18(2.44) 0  AA 71(8.95) 1(1.12) 
  total 739 80  total 793 89 
   P=0.123     P=0.001   
  Alleles     Alleles    
  T 0.851 0.913  G 0.706 0.837 
  C 0.149 0.088  A 0.294 0.163 
    P=0.011       P=<0.0001   
rs6933 Genotypes n(%) n(%) rs7211492 Genotypes n(%) n(%) 
  AA 233(30.26) 43(48.86)  AA 678(84.96) 83(93.26)
  AG 375(48.70) 32(36.36)  AG 112(14.04) 6(6.74) 
  GG 162(21.04) 13(14.77)  GG 8(1.00) 0 
  total 770 88  total 798 89 
   P=0.003     P=0.113   
  Alleles     Alleles    
  A 0.546 0.670  A 0.920 0.966 
  G 0.454 0.330  G 0.080 0.034 
    P=0.001       P=0.002   
rs8178826 Genotypes n(%) n(%) rs8178839 Genotypes n(%) n(%) 
  AA 745(97.01) 85(100.00)  TT 622(78.24) 66(75.00)
  AG 23(2.99) 0  TG 163(20.50) 21(23.86)
  GG 0 0  GG 10(1.26) 1(1.14) 
  total 768 85  total 795 88 
   P=0.156     P=0.703   
  Alleles     Alleles    
  T 0.985 1.000  T 0.885 0.869 
  C 0.015 0.000  G 0.115 0.131 
    P=<0.0001       P=0.558   
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Table 8 continued.  Distribution of APOH SNPs in whites and blacks 
APOH Genotype/   APOH Genotype/   
SNP Allele Whites Blacks SNP Allele Whites Blacks 
rs8178848 Genotypes n(%) n(%) rs8178858 Genotypes n(%) n(%) 
  GG 697(87.78) 78(89.66)  GG 461(63.67) 66(78.57)
  GA 92(11.59) 8(9.20)  GA 230(31.77) 16(19.05)
  AA 5(0.63) 1(1.15)  AA 33(4.56) 2(2.38) 
  total 794 87  total 724 84 
   P=0.475     P=0.025   
  Alleles     Alleles    
  G 0.936 0.943  G 0.796 0.881 
  A 0.064 0.057  A 0.204 0.119 
    P=0.718       P=0.002   
rs8178847 Genotypes n(%) n(%) rs3176975 Genotypes n(%) n(%) 
  GG 593(87.33) 59(85.51)  GG 448(60.79) 23(30.67)
  GA 83(12.22) 9(13.04)  GT 247(33.51) 34(45.33 
  AA 3(0.44) 1(1.45)  TT 42(5.70) 18(24.00)
  total 679 69  total 737 75 
   P=0.361     P=<0.0001   
  Alleles     Alleles    
  G 0.934 0.920  G 0.775 0.533 
  A 0.066 0.080  T 0.225 0.467 
    P=0.555       P=<0.0001   
rs1801689 Genotypes n(%) n(%) rs1801690 Genotypes n(%) n(%) 
  TT 613(92.04) 67(100.00)  GG 715(90.74) 84(98.82)
  TG 52(7.81) 0  GC 72(9.14) 1(1.18) 
  GG 1(0.15) 0  CC 1(0.13) 0 
  total 666 67  total 788 85 
   P=0.021     P=0.012   
  Alleles     Alleles    
  T 0.959 1.000  G 0.953 0.994 
  G 0.041 0.000  C 0.047 0.006 
    P=<0.0001       P=<0.0001   
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3.3 LINKAGE DISEQUILIBRIUM ANALYSIS OF APOH SNPs 
Pairwise linkage disequilibrium (LD) analysis was performed using Haploview statistical 
software for all 12 SNPs among white cases (Figure 10), white controls (Figure 11), and all 
white subjects combined (Figure 12).  LD was not examined for our black population due to 
small sample size.   
Both D' and r2 values are presented here to demonstrate the extent of LD between SNPs.  
The SNPs are aligned from left to right in the order in which they are located in the APOH gene 
(from promoter to 3' region).  Coding SNPs are marked with an ‘*’.  The highest r2 values 
generated from this analysis were observed in white cases only and included LD between 
APOH/8178847 and APOH/8178848 (r2=0.76), between APOH/8178847 and APOH/1801690 
(r2=0.60), and between  APOH/8178848 and APOH/1801690 (r2=0.58).  Similar r2 values were 
observed for white cases, controls, and all whites combined between APOH/8178839 and 
APOH/8178847 (r2=0.51) and between APOH/3760292 and APOH/3176975 (r2=0.53).   
There were several blocks of D' values equal to 1.0 in this analysis, more so in white 
cases than controls.  This is an example of “complete LD” without “perfect LD” – a concept that 
will be addressed in further detail in Section 4.1.2 of this paper. 
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Figure 10. LD analysis of white cases 
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 Figure 11. LD analysis of white controls 
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Figure 12. LD analysis of all white subjects 
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 3.4 ASSOCIATION OF APOH POLYMORPHISMS WITH SLE 
3.4.1 Association of APOH SNPs with SLE in whites and blacks 
The genotype and allele frequencies of twelve APOH SNPs were compared between 
cases and controls within white and black cohorts (Table 9).  Using a cut-off of P=0.05, no 
significant difference in genotype or allele distribution between patients with SLE and healthy 
controls was found for any of these twelve SNPs.  
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 Table 9. Distribution of APOH SNPs between cases and controls in whites and blacks 
APOH 
SNP Genotype/Allele Whites Blacks 
rs3760292 Genotypes Cases(%) Controls(%) Cases(%) Controls(%)
  TT 219(71.10) 318(73.78) 36(85.71) 30(78.95) 
  TC 82(26.62) 102(23.67) 6(14.29) 8(21.05) 
  CC 7(2.27) 11(2.55) 0 0 
  total 308 431 42 38 
   P=0.646 P=0.558 
  Alleles      
  T 0.844 0.856 0.929 0.895 
  C 0.156 0.144 0.071 0.105 
    P=0.525 P=0.453 
APOH 
SNP Genotype/Allele Whites Blacks 
rs6933 Genotypes Cases(%) Controls(%) Cases(%) Controls(%)
  AA 113(33.73) 120(27.59) 21(44.68) 22(53.66) 
  AG 157(46.87) 218(50.11) 17(36.17) 15(36.59) 
  GG 65(19.40) 97(22.30) 9(19.15) 4(9.76) 
  total 335 435 47 41 
   P=0.175 P=0.459 
  Alleles      
  T 0.572 0.526 0.628 0.720 
  C 0.428 0.474 0.372 0.280 
    P=0.077 P=0.192 
APOH 
SNP Genotype/Allele Whites Blacks 
rs8178826 Genotypes Cases(%) Controls(%) Cases(%) Controls(%)
  AA 318(97.25) 427(96.83) 45(100.00) 40(100.00) 
  AG 9(2.75) 14(3.17) 0 0 
  GG 0 (0.00) 0 0 
  total 327 441 45 40 
   P=0.832 P=1.000 
  Alleles      
  A 0.986 0.984 1.000 1.000 
  G 0.014 0.016 0.000 0.000 
    P=0.734 P= ---- 
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Table 9 continued. Distribution of APOH SNPs between cases and controls in whites and blacks 
APOH 
SNP Genotype/Allele Whites Blacks 
rs8178848 Genotypes Cases(%) Controls(%) Cases(%) Controls(%)
  GG 303(87.32) 394(88.14) 42(91.30) 36(87.80) 
  GA 40(11.53) 52(11.63) 3(6.52) 5(12.20) 
  AA 4(1.15) 1(0.22) 1(2.17) 0 
  total 347 447 46 41 
   P=0.301 P=0.467 
  Alleles      
  G 0.931 0.940 0.946 0.939 
  A 0.069 0.060 0.054 0.061 
    P=0.483 P=0.852 
APOH 
SNP Genotype/Allele Whites Blacks 
rs8178847 Genotypes Cases(%) Controls(%) Cases(%) Controls(%)
  GG 254(86.99) 339(87.60) 31(81.58) 28(90.32) 
  GA 36(12.33) 47(12.14) 6(15.79) 3(9.68) 
  AA 2(0.68) 1(0.26) 1(2.63) 0 
  total 292 387 38 31 
   P=0.781 P=0.596 
  Alleles      
  G 0.932 0.937 0.895 0.952 
  A 0.068 0.063 0.105 0.048 
    P=0.704 P=0.201 
APOH 
SNP Genotype/Allele Whites Blacks 
rs1801689 Genotypes Cases(%) Controls(%) Cases(%) Controls(%)
  TT 270(93.43) 343(90.98) 37(100.00) 32(100.00) 
  TG 18(6.23) 34(9.02) 0 0 
  GG 1(0.35) (0.00) 0 0 
  total 289 377 37 32 
   P=0.188 P=1.000 
  Alleles      
  T 0.965 0.955 1.000 1.000 
  G 0.035 0.045 0.000 0.000 
    P=0.328 P= ---- 
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Table 9 continued. Distribution of APOH SNPs between cases and controls in whites and blacks 
APOH 
SNP Genotype/Allele Whites Blacks 
rs2873966 Genotypes Cases(%) Controls(%) Cases(%) Controls(%) 
  GG 174(50.58) 223(49.67) 31(64.58) 30(73.17)) 
  GA 139(40.41) 186(41.43) 17(35.42) 10(24.39) 
  AA 31(9.01) 40(8.91) 0 1(2.44) 
  total 344 449 48 41 
   P=0.965 P=0.302 
  Alleles      
  G 0.708 0.704 0.823 0.854 
  A 0.292 0.296 0.177 0.146 
    P=0.860 P=0.577 
APOH 
SNP Genotype/Allele Whites Blacks 
rs7211492 Genotypes Cases(%) Controls(%) Cases(%) Controls(%) 
  AA 300(86.71) 378(83.63) 44(91.67) 39(95.12) 
  AG 43(12.43) 69(15.27) 4(8.33) 2(4.88) 
  GG 3(0.87) 5(1.11) 0 0 
  total 346 452 48 41 
   P=0.471 P=0.683 
  Alleles      
  A 0.929 0.913 0.958 0.976 
  G 0.071 0.087 0.042 0.024 
    P=0.221 P=0.516 
APOH 
SNP Genotype/Allele Whites Blacks 
rs8178839 Genotypes Cases(%) Controls(%) Cases(%) Controls(%) 
  TT 270(78.49) 352(78.05) 34(72.34) 32(78.05) 
  TG 67(19.48) 96(21.29) 12(25.53) 9(21.95) 
  GG 7(2.03) 3(0.67) 1(2.13) 0 
  total 344 451 47 41 
   P=0.201 P=0.895 
  Alleles      
  T 0.882 0.887 0.851 0.890 
  G 0.118 0.113 0.149 0.110 
    P=0.774 P=0.437 
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 Table 9 continued. Distribution of APOH SNPs between cases and controls in whites and blacks 
APOH 
SNP Genotype/Allele Whites Blacks 
rs8178858 Genotypes Cases(%) Controls(%) Cases(%) Controls(%)
  GG 215(63.99) 246(63.40) 34(72.34) 32(86.49) 
  GA 106(31.55) 124(31.96) 11(23.40) 5(13.51) 
  AA 15(4.46) 18(4.64) 2(4.26) 0 
  total 336 388 47 37 
   P=0.991 P=0.240 
  Alleles      
  G 0.798 0.794 0.840 0.932 
  A 0.202 0.206 0.160 0.068 
    P=0.858 P=0.054 
APOH 
SNP Genotype/Allele Whites Blacks 
rs3176975 Genotypes Cases(%) Controls(%) Cases(%) Controls(%)
  GG 195(60.00) 253(61.41) 11(26.19) 12(36.36) 
  GT 110(33.85) 137(33.25) 23(54.76) 11(33.33) 
  TT 20(6.15) 22(5.34) 8(19.05) 10(30.30) 
  total 325 412 42 33 
   P=0.844 P=0.187 
  Alleles      
  G 0.769 0.780 0.536 0.530 
  T 0.231 0.220 0.464 0.470 
    P=0.613 P=0.947 
APOH 
SNP Genotype/Allele Whites Blacks 
rs1801690 Genotypes Cases(%) Controls(%) Cases(%) Controls(%)
  GG 302(89.88) 413(91.37) 44(100.00) 40(97.56) 
  GC 33(9.82) 39(8.63) 0 1(2.44) 
  CC 1(0.30) (0.00) 0 0 
  total 336 452 44 41 
   P=0.446 P=0.482 
  Alleles      
  G 0.948 0.957 1.000 0.988 
  C 0.052 0.043 0.000 0.012 
    P=0.413 P=0.314 
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3.4.2 Haplotype associations with SLE 
The maximum number of SNPs that could be efficiently handled by our haplotype 
software is nine; therefore, the three coding SNPs that are not TagSNPs were excluded 
(APOH/8178847, APOH/1801689, and APOH/1801690).   
Nine-site haplotype analysis was performed using R software to determine the 
association of APOH TagSNPs with SLE in the entire white cohort, including 454 controls and 
349 cases.  Haplotype analysis was also performed using both EH and R software excluding all 
samples that had missing genotype information for any of the nine TagSNPs in the white cohort, 
including 320 controls and 256 cases.  R program results including all samples were largely 
consistent with the R program results excluding samples with missing data.  The EH and R 
program outputs that excluded samples calculated virtually identical haplotype frequencies; R 
program results are presented here, since this program is able to calculate P-values while EH is 
not.  Haplotype analysis was not carried out for the black population due to lack of a larger 
sample size. 
The parameters of the analysis included a minimum MAF of 0.01 and 18 degrees of 
freedom.  In total, 42 haplotypes were observed; the 11 most frequent haplotypes (pool 
frequency ≥ 0.01) are summarized in Table 10.  The alleles are aligned from left to right in 5' to 
3' orientation in the APOH gene (as listed below Table 10).  Major alleles are marked in bold 
type, while minor alleles are in regular type.   The frequencies of each haplotype in white cases, 
controls, and all whites are listed along with corresponding P-values.   Six of these haplotypes 
were significantly different between cases and controls (#’s 1, 2, 3, 5, 7, and 9, which are 
highlighted in Table 10).  Haplotypes that were more frequent in controls are marked in blue 
font, while haplotypes that were more frequent in cases are marked in red font.  There were four 
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common haplotypes that are present in greater than 10% of the population.  The overall 
difference in haplotypes of cases and controls was calculated by R software and was found to be 
significant (p<.0001). 
Table 10. Haplotype analysis of 9 TagSNPs in white cases and controls 
Haplotypes Case freq  
Control 
freq  Pool freq P-values 
 (n=256) (n=320)   
TATGAGGAA 0.144 0.228 0.199 0.031 
TATGGAGGA 0.121 0.196 0.163 0.006 
TATGGGGGA 0.103 0.191 0.159 0.002 
CATGGGTAA 0.114 0.129 0.123 0.587 
TATGGGGAA 0.162 0.006 0.064 <0.001 
TAGAGGGAA 0.055 0.053 0.055 0.794 
TATGGGTAG 0.021 0.055 0.042 0.017 
TAGGAGGGA 0.032 0.047 0.041 0.235 
TATGAGGGA 0.073 0.016 0.036 <0.001 
CATGGGTGA 0.017 0.007 0.012 0.210 
TGTGGGTAG 0.011 0.012 0.012 0.809 
 
Overall P-Value<0.0001 
 
TagSNPs: rs3760292,  rs8178826,  rs8178839,  rs8178848,  rs2873966, rs8178858,  rs3176975,  rs6933,  rs7211492 
3.5 ASSOCIATION OF APOH POLYMORPHISMS WITH RENAL DISEASE IN 
WHITE PATIENTS WITH SLE 
The genotype and allele frequencies of twelve APOH SNPs were compared between 
white cases with and without renal disease (Table 11).  This comparison was also performed for 
black cases with and without renal disease; however, due to small sample size and inability to 
interpret P-values these data are not shown.  Using a cut-off of P=0.05, only one significant 
difference in genotype or allele distribution between patients with SLE and healthy controls was 
found for these twelve SNPs.  The minor allele frequency of APOH/2873966 was significantly 
less for those with renal disease than those with no renal disease (p=0.023).  
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 Table 11. Distribution of APOH SNPs among white cases with and without renal involvement 
APOH Genotype/ No Renal Renal APOH Genotype/ No Renal Renal  
SNP Allele Disease  Disease SNP Allele  Disease Disease 
rs3760292 Genotypes n(%) n(%) rs2873966 Genotypes n(%) n(%) 
  TT 164(70.39) 55(73.33)   GG 116(46.96) 58(59.79)
  TC 63(27.04) 19(25.33)   GA 106(42.91) 33(34.02)
  CC 6(2.58) 1(1.33)   AA 25(10.12) 6(6.19) 
  total 233 75   total 247 97 
   P=0.888      P=0.098   
  Alleles      Alleles    
  T 0.839 0.860   G 0.684 0.768 
  C 0.161 0.140   A 0.316 0.232 
    P=0.526       P=0.023   
rs6933 Genotypes n(%) n(%) rs7211492 Genotypes n(%) n(%) 
  AA 83(34.30) 30(32.26)   AA 214(85.94) 86(88.66)
  AG 114(47.11) 43(46.24)   AG 32(12.85) 11(11.34)
  GG 45(18.60) 20(21.51)   GG 3(1.20) 0 
  total 242 93   total 249 97 
   P=0.829      P=0.716   
  Alleles      Alleles    
  A 0.579 0.554   A 0.924 0.943 
  G 0.421 0.446   G 0.076 0.057 
    P=0.563       P=0.337   
rs8178826 Genotypes n(%) n(%) rs8178839 Genotypes n(%) n(%) 
  AA 227(97.01) 91(97.85)   TT 194(78.23) 76(79.17)
  AG 7(2.99) 2(2.15)   TG 51(20.56) 16(16.67)
  GG 0 0   GG 3(1.21) 4(4.17) 
  total 234 93   total 248 96 
   P=1.000      P=0.165   
  Alleles      Alleles    
  T 0.985 0.989   T 0.885 0.875 
  C 0.015 0.011   G 0.115 0.125 
    P=0.655       P=0.717   
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 Table 11 continued. Distribution of APOH SNPs among white cases with and without renal involvement 
APOH Genotype/ No Renal Renal APOH Genotype/ No Renal Renal  
SNP Allele Disease  Disease SNP Allele  Disease Disease 
rs8178848 Genotypes n(%) n(%) rs8178858 Genotypes n(%) n(%) 
  GG 217(86.80) 86(88.66)   GG 158(65.02) 57(61.29)
  GA 30(12.00) 10(10.31)   GA 73(30.04) 33(35.48)
  AA 3(1.20) 1(1.03)   AA 12(4.94) 3(3.23) 
  total 250 97   total 243 93 
   P=0.879      P=0.595   
  Alleles      Alleles    
  G 0.928 0.938   G 0.800 0.790 
  A 0.072 0.062   A 0.200 0.210 
    P=0.626       P=0.773   
rs8178847 Genotypes n(%) n(%) rs3176975 Genotypes n(%) n(%) 
  GG 193(86.94) 61(87.14)   GG 140(59.32) 55(61.80)
  GA 28(12.61) 8(11.43)   GT 79(33.47) 31(34.83)
  AA 1(0.45) 1(1.43)   TT 17(7.20) 3(3.37) 
  total 222 70   total 236 89 
   P=0.656      P=0.497   
  Alleles      Alleles    
  G 0.932 0.929   G 0.761 0.792 
  A 0.068 0.071   T 0.239 0.208 
    P=0.876       P=0.384   
rs1801689 Genotypes n(%) n(%) rs1801690 Genotypes n(%) n(%) 
  TT 205(93.18) 65(94.20)   GG 224(89.96) 78(89.66)
  TG 14(6.36) 4(5.80)   GC 24(9.64) 9(10.34) 
  GG 1(0.45) 0   CC 1(0.40) 0 
  total 220 69   total 249 87 
   P=1.000      P=0.879   
  Alleles      Alleles    
  T 0.964 0.971   G 0.948 0.948 
  G 0.036 0.029   C 0.052 0.052 
    P=0.661       P=0.980   
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3.6 ASSOCIATION OF APOH POLYMORPHISMS WITH ANTIPHOSPOHLIPID 
ANTIBODIES (APA) IN WHITES AND BLACKS 
The genotype and allele frequencies of twelve APOH SNPs were compared between 
APA negative and APA positive groups stratified by race (Table 12).  Subjects that were “APA 
positive” included those that were positive for any of the three antipohospohlipid antibodies 
(aCL, LAC, and anti-apoH).  APA negative individuals included those who were not positive for 
any of the APA.  Only one significant difference was observed, and this was between allele 
frequencies of black cases and controls for APOH/8178848 (p=0.041). 
Each of the twelve APOH SNPs was also analyzed for association with aCL, LAC, and 
anti-apoH separately in all subjects stratified by race.  No significant differences were observed 
in these comparisons (data not shown).   
In addition, Each of the twelve APOH SNPs was analyzed for association with aCL, 
LAC, anti-apoH, and any APA separately in cases and controls stratified by race.  Once again, no 
significant difference was observed for these comparisons (data not shown).   
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 Table 12. Distribution of APOH SNPs among whites and blacks with and without APA 
APOH      
SNP Genotype/Allele Whites Blacks 
rs3760292 Genotypes APA -(%) APA+(%) APA -(%) APA+(%) 
  TT 231(73.57) 253(71.67) 22(81.48) 38(82.61) 
  TC 77(24.52) 89(25.21) 5(18.52) 8(17.39) 
  CC 6(1.91) 11(3.12) 0 0 
  total 314 353 27 46 
   P=0.616 P=1.000 
  Alleles      
  T 0.858 0.843 0.907 0.913 
  C 0.142 0.157 0.093 0.087 
    P=0.427 P=0.909 
APOH      
SNP Genotype/Allele Whites Blacks 
rs6933 Genotypes APA -(%) APA+(%) APA -(%) APA+(%) 
  AA 85(27.33) 117(32.87) 12(42.86) 21(45.65) 
  AG 156(50.16) 167(46.91) 13(46.43) 17(36.96) 
  GG 70(22.51) 72(20.22) 3(10.71) 8(17.39) 
  total 311 356 28 46 
   P=0.294 P=0.612 
  Alleles      
  T 0.524 0.563 0.661 0.641 
  C 0.476 0.437 0.339 0.359 
    P=0.153 P=0.810 
APOH      
SNP Genotype/Allele Whites Blacks 
rs8178826 Genotypes APA -(%) APA+(%) APA -(%) APA+(%) 
  AA 301(95.86) 349(97.21) 27(100.00) 45(100.00)
  AG 13(4.14) 10(2.79) 0 0 
  GG 0 (0.00) 0 0 
  total 314 349 27 45 
   P=0.397 P=1.000 
  Alleles      
  A 0.979 0.986 1.000 1.000 
  G 0.021 0.014 0.000 0.000 
    P=0.345 P= ---- 
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 Table 12 continued. Distribution of APOH SNPs among whites and blacks with and without APA 
APOH      
SNP Genotype/Allele Whites Blacks 
rs8178848 Genotypes APA -(%) APA+(%) APA -(%) APA+(%) 
  GG 284(87.93) 324(87.57) 27(96.43) 38(84.44) 
  GA 37(11.46) 43(11.62) 1(3.57) 6(13.33) 
  AA 2(0.62) 3(0.81) 0 1(2.22) 
  total 323 370 28 45 
   P=1.000 P=0.304 
  Alleles      
  G 0.937 0.934 0.982 0.911 
  A 0.063 0.066 0.018 0.089 
    P=0.836 P=0.041 
APOH      
SNP Genotype/Allele Whites Blacks 
rs8178847 Genotypes APA -(%) APA+(%) APA -(%) APA+(%) 
  GG 262(86.75) 281(87.27) 23(92.00) 33(80.49) 
  GA 38(12.58) 40(12.42) 2(8.00) 7(17.07) 
  AA 2(0.66) 1(0.31) 0 1(2.44) 
  total 302 322 25 41 
   P=0.890 P=0.667 
  Alleles      
  G 0.930 0.935 0.960 0.890 
  A 0.070 0.065 0.040 0.110 
    P=0.761 P=0.115 
APOH      
SNP Genotype/Allele Whites Blacks 
rs1801689 Genotypes APA -(%) APA+(%) APA -(%) APA+(%) 
  TT 273(91.30) 293(92.43) 25(100.00) 39(100.00)
  TG 25(8.36) 24(7.57) 0 0 
  GG 1(0.33) (0.00) 0 0 
  total 299 317 25 39 
   P=0.710 P=1.000 
  Alleles      
  T 0.955 0.962 1.000 1.000 
  G 0.045 0.038 0.000 0.000 
    P=0.522 P= ---- 
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 Table 12 continued. Distribution of APOH SNPs among whites and blacks with and without APA 
APOH      
SNP Genotype/Allele Whites Blacks 
rs2873966 Genotypes APA -(%) APA+(%) 
APA -
(%) APA+(%)
  GG 156(48.60) 190(51.49) 19(67.86) 34(72.34) 
  GA 139(43.30) 145(39.30) 9(32.14) 13(27.66) 
  AA 26(8.10) 34(9.21) 0 0 
  total 321 369 28 47 
   P=0.557 P=0.794 
  Alleles      
  G 0.702 0.711 0.839 0.862 
  A 0.298 0.289 0.161 0.138 
    P=0.718 P=0.712 
APOH      
SNP Genotype/Allele Whites Blacks 
rs7211492 Genotypes APA -(%) APA+(%) 
APA -
(%) APA+(%)
  AA 272(83.95) 314(84.86) 25(89.29) 45(95.74) 
  AG 49(15.12) 52(14.05) 3(10.71) 2(4.26) 
  GG 3(0.93) 4(1.08) 0 0 
  total 324 370 28 47 
   P=0.927 P=0.356 
  Alleles      
  A 0.915 0.919 0.946 0.979 
  G 0.085 0.081 0.054 0.021 
    P=0.798 P=0.336 
APOH      
SNP Genotype/Allele Whites Blacks 
rs8178839 Genotypes APA -(%) APA+(%) 
APA -
(%) APA+(%)
  TT 251(78.19) 286(77.30) 23(82.14) 31(67.39) 
  TG 65(20.25) 80(21.62) 5(17.86 14(30.43) 
  GG 5(1.56) 4(1.08) 0 1(2.17) 
  total 321 370 28 46 
   P=0.808 P=0.326 
  Alleles      
  T 0.883 0.881 0.911 0.826 
  G 0.117 0.119 0.089 0.174 
    P=0.904 P=0.123 
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 Table 12 continued. Distribution of APOH SNPs among whites and blacks with and without APA 
APOH      
SNP Genotype/Allele Whites Blacks 
rs8178858 Genotypes APA -(%) APA+(%) APA -(%) APA+(%)
  GG 175(60.98) 216(63.53) 20(76.92) 37(84.09) 
  GA 97(33.80) 108(31.76) 6(23.08) 7(15.91) 
  AA 15(5.23) 16(4.71) 0 0 
  total 287 340 26 44 
   P=0.825 P=0.531 
  Alleles      
  G 0.779 0.794 0.885 0.920 
  A 0.221 0.206 0.115 0.080 
    P=0.509 P=0.498 
APOH      
SNP Genotype/Allele Whites Blacks 
rs3176975 Genotypes APA -(%) APA+(%) APA -(%) APA+(%)
  GG 177(60.20) 210(60.00) 9(34.62) 11(29.73) 
  GT 99(33.67) 120(34.29) 12(46.15) 15(40.54) 
  TT 18(6.12) 20(5.71) 5(19.23) 11(29.73) 
  total 294 350 26 37 
   P=0.965 P=0.686 
  Alleles      
  G 0.770 0.771 0.577 0.500 
  T 0.230 0.229 0.423 0.500 
    P=0.965 P=0.392 
APOH      
SNP Genotype/Allele Whites Blacks 
rs1801690 Genotypes APA -(%) APA+(%) APA -(%) APA+(%)
  GG 292(90.40) 340(90.67) 28(100.00) 47(97.92) 
  GC 31(9.60) 34(9.07) 0 1(2.08) 
  CC 0 1(0.27) 0 0 
  total 323 375 28 48 
   P=0.944 P=1.000 
  Alleles      
  G 0.952 0.952 1.000 0.990 
  C 0.048 0.048 0.000 0.010 
    P=0.999 P=0.315 
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4.0  DISCUSSION 
Systemic lupus erythematosus (SLE) is an autoimmune disease of great public health 
import, the etiology of which is as yet poorly understood.  One glycoprotein in particular, apoH, 
is known to complex with phospholipids and form an autoantigen that is recognized by 
antibodies present in autoimmune diseases such as SLE.  These antiphospholipid antibodies 
(aCL, LAC, and anti-apoH) are of great clinical relevance due to their association with 
antiphospholipid antibody syndrome (APS), thrombosis, and SLE.   
While some studies have identified functional polymorphisms in the coding regions of 
the APOH gene, intronic polymorphisms have not yet been analyzed.  Further, TagSNPs have 
not previously been used in an association study with APOH and lupus.  Since it is nearly 
impossible to analyze all  of the polymorphisms in the APOH gene individually, TagSNPs are 
particularly useful to work with as any associations that are found to exist between a TagSNP 
and disease factors may indicate that one or more SNPs that are in linkage disequilibrium with 
the TagSNP could be involved in the association. 
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4.1 ASSOCIATION OF APOH POLYMORPHISMS WITH RACE  
4.1.1 Distribution of APOH SNPs in whites and blacks 
The frequencies of the APOH SNPs that were analyzed in this study have been reported 
for sample groups of African and Caucasian descent by both the Seattle SNP database and the 
HapMap project; however, these samples were small (n=23 for whites, n=24 for blacks in the 
Seattle SNP database, and n=60 for both subgroups in HapMap).  In our larger Pittsburgh 
cohorts,  significant allelic distribution differences between whites and blacks were found for 
nine of the twelve SNPs, while significant genotype differences were found for six SNPs.          
For one TagSNP (APOH/rs3176975), the minor allele frequency (MAF) was significantly 
less for white subjects (0.225) compared to black subjects (0.467).  A similar trend was reported 
by the Seattle SNP database (Table 13).  The genotype distribution for this coding TagSNP was 
also significantly different between whites and blacks.   
All of the other significant differences that were observed indicated a lower MAF in 
black subjects compared to white subjects.  For APOH/rs8178858, the frequency of the minor 
allele (A) was 0.119 and 0.204 in blacks and whites, respectively.  This MAF in blacks was more 
than twice the frequency reported by the Seattle SNP database (0.05), while the white MAF was 
similar (Table 13).  The genotype distribution for this intronic TagSNP was also significantly 
different between whites and blacks. 
For APOH/rs2873966, the frequency of the minor allele (A) was 0.163 and 0.294 in 
blacks and whites, respectively.  A similar trend was reported by the Seattle SNP database (Table 
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13).  The genotype distribution for this intronic TagSNP was also significantly different between 
whites and blacks.   
For APOH/rs6933, the frequency of the minor allele (G) was 0.330 and 0.454 in blacks 
and whites, respectively.  This MAF in blacks was almost twice the frequency reported by the 
Seattle group (0.18), while the white MAF was similar (Table 13).  The genotype distribution for 
this TagSNP located in the 3′UTR was also significantly different between whites and blacks. 
For APOH/rs1801689, the frequency of the minor allele (G) was 0.041 in whites and it 
was not present in blacks.  HapMap reported the MAF to be 0.025 in whites and similarly absent 
in blacks (Table 13).  The genotype distribution for this coding SNP was also significantly 
different between whites and blacks.   
For APOH/rs1801690, the frequency of the minor allele (C) was 0.006 and 0.047 in 
blacks and whites, respectively.  This MAF in whites was twice the frequency reported by the 
Seattle SNP database (0.02), while the allele was absent in blacks (Table 13).  The genotype 
distribution for this coding SNP was also significantly different between whites and blacks.  The 
single individual with the GC genotype in our Pittsburgh cohort may suggest a very low MAF in 
the African population, Caucasian admixture in this individual’s ancestry, or a new mutation.  
For APOH/rs3760292, the frequency of the minor allele (C) was 0.088 and 0.149 in 
blacks and whites, respectively.  This MAF in blacks was about half as frequent as reported by 
the Seattle SNP database (0.17), while the white MAF was similar (Table 13).  The genotype 
distribution for this promoter TagSNP was not significantly different between whites and blacks. 
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For APOH/rs7211492, the frequency of the minor allele (G) was 0.034 and 0.080 in 
blacks and whites, respectively.  A similar trend was reported by the Seattle SNP database (Table 
13).  The genotype distribution for this TagSNP located in the 3′ flanking region was not 
significantly different between whites and blacks.   
For APOH/rs8178826, the frequency of the minor allele (G) was 0.015 in whites and it 
was not present in blacks.  The Seattle SNP database found the MAF to be 0.05 in whites and 
similarly absent in blacks (Table 13). The genotype distribution for this intronic TagSNP was not 
significantly different between whites and blacks.   
These associations must all be interpreted under the caveat that the black sample size was 
9 to 10 times smaller than the white sample size, with black sample sizes ranging from 67 to 89 
individuals (depending on the SNP) (Table 8).  Therefore, minor alleles with a very low 
frequency (especially less than 10%) might have been mis-represented due to sampling error, 
causing misleading p-values to be generated.  All studies to date that have reported the 
frequencies of these SNPs in individuals of African descent have had small sample sizes, thus it 
is difficult to infer that our observed frequencies truly reflect the general population.  All caveats 
aside, significant differences in the distribution of several APOH SNPs between whites and 
blacks were observed in this study; therefore, other analyses were performed in races separately. 
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Table 13. Minor allele frequencies (MAF) of APOH SNPs 
 
Db SNP ID MAF in Whites MAF in Blacks 
 Seattle SNP  
*HapMap 
Pittsburgh  Seattle SNP  
*HapMap 
Pittsburgh  
rs3760292 .17 .149 .17 .088 
rs8178826 .05 .015 .00 .00 
rs8178839 .07 .115 .17 .131 
rs8178847 .07 .066 .05 .080 
rs8178848 .05 .064 .03 .057 
rs2873966 .22 .294 .19 .163 
rs8178858 .24 .204 .05 .119 
rs3176975 .26 .225 .50 .467 
rs1801689 .025* .041 .00* .00 
rs1801690 .02 .047 .00 .006 
rs6933 .48 .454 .18 .330 
rs7211492 .12 .080 .03 .034 
 
4.1.2 Linkage disequilibrium analysis of APOH SNPs 
Hardy-Weinberg equilibrium tells us how genotype frequencies at a single locus behave 
under a set of assumptions; however, to gain information about how genotype frequencies over 
two or more loci behave (ie, independently or dependently), linkage disequilibrium (LD) analysis 
is useful. 
It is not yet possible to predict whether most noncoding polymorphisms have functional 
consequences.  Testing candidate SNPs directly is a useful strategy because information gained 
about the disease association of one SNP has implications for other SNPs.  For example, a lack 
of association found in one SNP would rule out functionally important changes at SNPs that are 
in tight LD with the candidate SNP (Carlson et al. 2004).  Further, when a set of densely spaced 
  55
TagSNPs within one gene are directly tested, information can be indirectly gained about those 
unassayed SNPs that are in the same bin. 
In this study, pairwise linkage disequilibrium (LD) analysis was performed for twelve 
APOH SNPs among white cases, white controls, and all white subjects combined.  LD for the 
black population was not analyzed due to small sample size.  One way LD is quantified is by D – 
a measure of how far off gamete frequencies are from what you’d expect (H0) if no LD were 
present.  D' (D/Dmax) is a measure of how “scientifically significant” an observed correlation may 
be. 
The results of this analysis revealed several D' values of 1.0, indicating that the allelic 
association is as strong as possible, given the allele frequencies at two sites.  This is referred to as 
“complete LD.”  This is not surprising since these APOH SNPs are linked (located in close 
proximity).  SNPs can be linked without being in linkage disequilibrium, since LD only exists if 
there is an association with a population.  Further, pairwise LD analysis can yield only three 
haplotypes, not only if there is true correlation, but also if the minor allele frequencies of SNPs 
are so low that the fourth haplotype (with both minor alleles) is not seen.  In our analysis, this 
may have been the case since we were dealing with several SNPs with low minor allele 
frequencies.   
A problem with D' is that a D' of 1.0 can be observed even if there is low correlation.  For 
low allele frequencies, r2 has more reliable sample properties than D'.  Only when genotypes are 
perfectly correlated does r2 equal 1.0 (“perfect LD”), and this can only occur if the MAFs are 
equal (Carlson et al. 2004).  The highest r2 value observed between these twelve SNPs was 0.76 
between APOH/rs8178847 and APOH/rs8178848 for the white cases only.  For the majority of 
blocks, the r2 was relatively low.  Since this analysis was performed with nine TagSNPs, these 
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results are understandable using the rational that the TagSNPs are known to be in LD with other 
SNPs (not analyzed in this study), but not necessarily each other.   
4.2 ASSOCIATION OF APOH POLYMORPHISMS WITH SLE 
4.2.1 Association of APOH SNPs with SLE in whites and blacks 
The apoH protein has been shown to have anti-atherogenic properties in addition to 
playing a role as a major target antigen for APA present in patients with APS and secondary 
APS, which may exist in concert with autoimmune diseases such as SLE.  For these reasons, 
researchers have been interested in the relationship that APOH may have with SLE.  Studies 
have found instances of functional polymorphisms in APOH, and association analyses have been 
performed to investigate the impact of these polymorphisms on disease risk (Steinkasserer et al. 
1993; Sanghera et al. 1997b; Kamboh et al. 2004).  In theory, when the function of a gene is 
altered by SNPs, there may be phenotypic consequence.  Therefore, association analyses of 
individual APOH SNPs with SLE were performed for our study.   
Association of each SNP with SLE was analyzed in whites and blacks separately by 
comparing genotype and allele frequencies in cases and controls.  Results revealed no clear-cut 
associations of APOH SNPs with SLE risk.  The lowest P-value observed was between allele 
frequencies of black cases and controls in APOH/rs8178858 (p=0.054), indicating borderline 
significance (our sample size was small, however, so this result must be interpreted with 
caution).   
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Most of the observed P-values for this analysis were large, meaning there was not enough 
evidence to reject the null hypothesis.  This could be due to either a true lack of association or to 
our relatively small sample sizes (especially in the black cohort), and several SNPs with low 
MAFs.  Therefore, our results warrant further investigation of the association of these APOH 
SNPs with SLE.    
4.2.2 Haplotype associations with SLE 
The maximum number of SNPs that could be efficiently handled by our haplotype 
software is nine; therefore, the three coding SNPs that were not TagSNPs (located in codons 136, 
306, and 316) were excluded from haplotype analysis.  EH and R statistical programs were used 
to analyze white cases and controls (excluding all samples with missing genotypes for any of the 
TagSNPs).  These two programs yielded virtually identical haplotype frequencies.  EH, however, 
is not able to generate meaningful P-values for an analysis of nine SNPs, given the high degree 
of freedom (df=511).  R program sets a lower degree of freedom (df=18); therefore, P-values 
could be calculated by this program (R program output is reported in this document). 
Haplotype analysis of 9 APOH TagSNPs in the white population revealed an overall 
significant difference between the distribution of haplotypes between cases and controls 
(p<0.0001), indicating the greater informative value of haplotype analysis compared to 
individual SNP analysis.  There were four common haplotypes that are present in greater than 
10% of the population (Haplotype #’s 1-4).  Of the 11 most frequent haplotypes (pool frequency 
≥ 0.01), six differed significantly between cases and controls (Haplotype #’s 1, 2, 3, 5, 7, and 9). 
Haplotype #’s 1, 2, 3, and 7 were significantly more frequent in the white control population 
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compared to white cases, suggesting a protective effect.  In contrast, haplotype #’s 5 and 9 were 
more frequent in cases compared to healthy controls, indicating a potential risk factor for SLE.   
The haplotypes with the most statistical significance (p=<0.001) were #’s 5 and 9.  Of 
particular interest is haplotype #5, which is present in 16.2% of cases vs. 0.6% of controls (about 
27 times more frequent in cases).  This haplotype also contains the major allele from each 
TagSNP.  Such a finding is interesting, since one would expect the most common haplotype to 
contain all of the major alleles; however in this study, it appears that the most common 
haplotype, #1, which exists in 19.9% of the total population (14.4% and 22.8% of cases and 
controls, respectively), contains the minor allele for APOH/rs2873966.  This is the second most 
common TagSNP, with a MAF of 29.4% in our population.  The next three most frequent 
haplotypes account for 44.5% of our population collectively.  Given the fact that most of the 
TagSNPs used in this study are relatively rare in the general population, it is feasible that there is 
no one very frequent haploytpe.  
It is possible that the reason why more significance was found by haplotype analysis than 
single site (LD) analysis is that several small single site effects could be additive when evaluated 
in sum.  However, the most likely explanation is that untested and potentially functional variants 
are present on those haplotypes.  Sequencing of these haplotypes in future studies may identify 
the functional variants.   
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4.3 ASSOCIATION OF APOH POLYMORPHISMS WITH RENAL DISEASE IN 
WHITE PATIENTS WITH SLE 
As previously mentioned, lupus nephritis is one of the most common clinical 
manifestations of SLE, and polymorphisms in several genes have been shown to be associated 
with its occurrence.  For example, an allele in PDCD1 (PD-1.3A) has been shown to be 
associated with renal manifestations in SLE patients from northern Sweden (Johansson et al. 
2005).  In addition, Tripi et al. (2006) identified three promoter SNPs in PON1 that were 
significantly associated with lupus nephritis.  The underlying mechanism of this association is 
not yet determined; however, it is believed that increased susceptibility of LDL to oxidation in 
renal disease may be one explanation (Tripi et al. 2006).
To determine a possible association of APOH SNPs with lupus nephritis, the genotype 
and allele frequencies of twelve APOH SNPs were compared between white cases with and 
without renal disease.  No associations between genotype distributions of the twelve APOH 
SNPs and renal disease in white patients with SLE were observed.  Only one significant 
difference in allele distribution was found.  The minor allele frequency of APOH/2873966 was 
significantly less for those with no renal disease than those with renal disease (P=0.023, 
MAF=0.232 vs. MAF=0.316).  There were 97 patients in the group with no renal disease, which 
is a relatively small population; therefore, although this finding may warrant further 
investigation, it must be interpreted with the caveat of low statistical power.  Further 
investigation could involve repeating the analysis with a larger patient sample or investigating 
associations between SNPs in the same bin as the APOH/2873966 TagSNP with renal disease in 
SLE patients. 
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4.4 ASSOCIATION OF APOH POLYMORPHISMS WITH ANTIPHOSPOHLIPID 
ANTIBODIES (APA) IN WHITES AND BLACKS 
Antiphospholipid antibodies (APA) are known to be associated with several clinical 
manifestations of SLE, and apoH is the main target antigen for APA.  The prevalence of anti-
apoH antibodies has been shown to be greater than 30% in SLE patients of white ancestry 
(Kamboh et al. 1999) and 51% in Nigerian blacks (Kamboh et al. 2004).  Several other studies 
have found the prevalence of anti-apoH antibodies to be 49-77% of patients with 
antiphospholipid syndrome (APS) of various ancestries, including white, African American, 
Asian, and Hispanic (Hirose et al. 1999; Atsumi et al. 1999; Prieto et al. 2003).   
Association studies of several APOH polymorphisms with APA have been published.  
For example, the Val247Leu polymorphism has been shown to be associated with anti-apoH in 
patients with APS (Hirose et al. 1999; Atsumi et al. 1999; Prieto et al. 2003), but not in patients 
with SLE (Kamboh et al. 1999), secondary APS (Atsumi et al. 1999), or a general African black 
sample (Kamboh et al. 2004).  Two functional polymorphisms in the fifth domain of apoH 
(Cys306Gly and Trp316Ser) have been shown to disrupt the normal binding of anionic 
phospholipids to apoH (Sanghera et al. 1997b; Mehdi et al. 2000).  Three missense mutations in 
the third domain of apoH (Ile122Thr, Arg135His, and Ala141Asp) have been shown to affect the 
binding of cardiolipin to apoH (Kamboh et al. 2004). 
In order to ascertain any association of twelve APOH SNPs with APA in patients with 
SLE, the genotype and allele frequencies of these SNPs were compared between white and black 
SLE cohorts that were APA negative or APA positive.  Subjects that were “APA positive” 
included those that were positive for any of three antipohospohlipid antibodies: aCL, LAC, and 
β2-GPI.  No associations between genotype distributions of each of the twelve APOH SNPs and 
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whites and blacks that were APA negative or APA positive were observed.  Only one significant 
difference was observed between allele frequencies of black cases and controls for one intronic 
TagSNP, APOH/8178848 (p=0.041).  The black sample size was small, so future studies with a 
larger sample size may be needed to further investigate this preliminary association.  Other 
future directions could involve investigating associations between SNPs in the same bin as the 
APOH/8178848 TagSNP with APA in SLE patients. 
Each of the twelve APOH SNPs were also analyzed for association with aCL, LAC, and 
anti-apoH separately in SLE subjects stratified by race.  No significant differences were observed 
in these comparisons.  In addition, SNP genotype and allele associations with APA were 
analyzed in black and white cases and controls; once again, no significant differences were 
observed for this comparison.   
The lack of significant association between these APOH SNPs and APA could be 
explained by a small black cohort.  It is interesting that studies in the past found associations 
with the nonsynonymous coding SNPs ; however, our sample is larger than some of these past 
studies so the power of the statistical analysis of this study may be greater.   
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4.5 CONCLUSIONS 
In this study, twelve APOH SNPs, including 5 intronic TagSNPs, one TagSNP in the 
3′UTR, one TagSNP in the 3′ flanking region, one promoter TagSNP, one coding TagSNP, and 
three coding SNPs, were genotyped in SLE patients and healthy controls.  Association tests were 
conducted comparing allele and genotype distributions of these SNPs with SLE, race, renal 
disease, and APA in patients with SLE.  In addition, linkage disequilibrium (LD) analysis 
between all twelve APOH SNPs in white cases and controls and 9-site haplotype analysis 
including TagSNPs in all white subjects were performed.  The results of these analyses are 
summarized here: 
1) The distribution of allele frequencies was significantly different between blacks and 
whites for 9 of the 12 APOH SNPs analyzed 
2) Pairwise LD analysis revealed complete LD (D'=1.0) between several APOH SNPs; 
however there were no r2 values over 0.80, indicating a lack of high correlation. 
3) The haplotype pattern of nine TagSNPs in the white samples was significantly different 
between cases and controls (p<0.0001).  Two haplotypes had significantly higher 
frequency in cases (indicating potential disease risk), while four haplotypes had 
significantly higher frequency in controls (indicating potential disease protection).   
4) No associations between genotype or allele distributions in any of the twelve APOH 
SNPs and SLE in whites or blacks were observed.   
5) No associations between genotype distributions were observed in any of the twelve 
APOH SNPs and renal disease in whites with SLE. 
6) No associations between genotype distributions in any of the twelve APOH SNPs and 
whites and blacks that were APA negative or APA positive were observed.   
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